

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 November 2023 (30.11.2023)



(10) International Publication Number
WO 2023/230190 A1

(51) International Patent Classification:

C07D 451/02 (2006.01) C07D 519/00 (2006.01)
C07D 487/04 (2006.01) A61P 35/00 (2006.01)
C07D 495/00 (2006.01) A61K 31/506 (2006.01)

(21) International Application Number:

PCT/US2023/023445

(22) International Filing Date:

24 May 2023 (24.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/345,794 25 May 2022 (25.05.2022) US
63/380,544 21 October 2022 (21.10.2022) US
63/486,934 24 February 2023 (24.02.2023) US

(71) Applicant: QUANTA THERAPEUTICS, INC. [US/US];
455 Mission Bay Boulevard South, San Francisco, California 94158-2158 (US).

(72) Inventors: LIN, Hong; 455 Mission Bay Boulevard South, San Francisco, California 94158-2158 (US). LUENGO, Juan; 455 Mission Bay Boulevard South, San Francisco, California 94158-2158 (US). JOHNSON, Neil; 455 Mission Bay Boulevard South, San Francisco, California 94158-2158 (US). HOSPITAL, Audrey; 455 Mission Bay Boulevard South, San Francisco, California 94158-2158 (US). ZENG, Jin; 455 Mission Bay Boulevard South, San Francisco, California 94158-2158 (US).

(74) Agent: MARTINEZ, Jose; WILSON SONSINI GOODRICH & ROSATI, P.C., 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PYRIMIDINE BASED MODULATORS AND USES THEREOF

(57) Abstract: Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one thereof, useful for modulating KRAS G12 and/or other G12 mutants.



WO 2023/230190 A1